[CLSTR]
API
< Back to all clusters
[HEALTH] · 2 sources

started · updated

Part of situation: Tozorakimab clinical trials for COPD (2 clusters)

Tozorakimab shows sustained COPD exacerbation reduction in 104-week study

tozorakimab COPD interleukin-33 monoclonal antibody clinical trials

An integrated analysis of the phase 3 OBERON, TITANIA, and PROSPERO clinical trials indicates that tozorakimab, an investigational anti-interleukin-33 (IL-33) monoclonal antibody, sustained reductions in chronic obstructive pulmonary disease (COPD) exacerbations for up to 104 weeks.

The study, presented at the CHEST 2026 Annual Meeting, included 884 patients receiving tozorakimab and 866 receiving a placebo. In the overall population of current and former smokers, the annualized exacerbation rate was 0.26 with tozorakimab compared to 0.36 with the placebo.

While the drug showed efficacy, it narrowly missed its primary endpoint for severe exacerbations specifically in former smokers, with a rate of 0.26 for tozorakimab versus 0.33 for placebo (P= .0587).

Entities

University of Lübeck

Sources

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD [www.consultantlive.com]
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD | HCPLive [www.hcplive.com]